Elicio Therapeutics, Inc.

NASDAQ:ELTX

Biotechnology

Healthcare
$2.70 -18.90%

-$0.89 today

Market cap
$51.48M
Beta
1.14
P/E (TTM)
-1.7
EPS (TTM)
-$2.21
52W Low $2.66High $16.00

Volume 0.41M

Average 0.34M

ELTX EBITDA Margin

EBITDA as a percentage of revenue.

Elicio Therapeutics, Inc.NASDAQ: ELTX

EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026

EBITDA Margin not reported for Q1 FY2026

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
—— QoQ
Last fiscal yearDec 2025
—— YoY
LTMMar 2026
—— YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3 years———
5 years——
10 years——

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2021
-183.4%
Year-over-year change
—
Reported Analyst consensus estimate

EBITDA Margin vs competitors

How ELTX compares with its peers on the latest reported figures

ELTX Competitors Peer median
EBITDA Margin for ELTX and competitors
Company Period LTM level YoY 3-year change
RANIRani Therapeutics Holdings, Inc.LTM Mar 2026-1053.3% +3016.0 pp—
MISTMilestone Pharmaceuticals Inc.LTM Mar 2026-3439.7% —-2679.5 pp
CRDFCardiff Oncology, Inc.LTM Mar 2026-8329.5% -111.2 pp+2386.2 pp
ELTXElicio Therapeutics, Inc.FY2025— ——
PEPGPepGen Inc.FY2025— ——
CRBPCorbus Pharmaceuticals Holdings, Inc.FY2025— ——
NKTXNkarta, Inc.FY2025— ——
MOLNMolecular Partners AGFY2025— ——
ACTUActuate Therapeutics IncFY2025— ——
Peer median (excluding ELTX) -3439.7%+1452.4 pp-146.6 pp

Competitors are the stored peer set for ELTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue28.31M0000
Cost of Revenue1.23M1.06M1.17M1.18M1.13M
Gross Profit27.08M(1.06M)(1.17M)(1.18M)(1.13M)
Gross Margin95.6%————
Research & Development48.61M17.05M22.68M33.66M24.9M
Selling, General & Admin17.78M5.63M11.9M11.33M12.81M
Operating Expenses66.39M22.68M34.58M43.81M36.59M
Depreciation & Amortization801K1.06M1.17M1.18M1.13M
EBITDA(51.93M)(23.55M)(32.97M)(50.27M)(37.31M)
EBITDA Margin-183.4%————
Operating Income(39.31M)(23.73M)(35.75M)(44.99M)(37.71M)
Operating Margin-138.8%————
Interest Income3.39K64.83K373K777K776K
Interest Expense876.44K3.6M1.06M455K1.13M
Other Income / Expenses(15.27M)(4.48M)550K(6.91M)(1.86M)
Income Before Tax(54.57M)(28.21M)(35.2M)(51.9M)(39.57M)
Pre-Tax Margin-192.8%————
Income Tax Expense00000
Net Income(26.4M)(28.21M)(35.2M)(51.9M)(39.57M)
Net Margin-93.2%————
EPS (Basic)(19.32)(9.10)(6.96)(4.25)(2.58)
EPS (Diluted)(19.32)(9.10)(6.96)(4.25)(2.58)
Weighted Avg Shares3.2M3.1M5.06M12.2M15.31M
Weighted Avg Shares (Diluted)3.2M3.1M5.06M12.2M15.31M

Elicio Therapeutics, Inc.

NASDAQ:ELTX

Intrinsic Alpha fair value

Locked

Current Price

$2.70

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.